Literature DB >> 25980896

Psychological distress related to BRCA testing in ovarian cancer patients.

Merete Bjørnslett1,2, Alv A Dahl3,4, Øystein Sørebø5, Anne Dørum6.   

Abstract

An increasing demand for genetic testing has moved the procedure from highly selected at-risk individuals, now also including cancer patients for treatment associated testing. The heritable fraction of ovarian cancer is more than 10%, and our department has offered BRCA testing to such patients irrespective of family history since 2002. This study examined potential psychosocial distress associated with this procedure using The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire and other patient-rated generic distress instruments. Patients were divided into four groups according to cancer risk: mutation carriers, own history of breast cancer and ovarian cancer, family history of breast cancer and/or ovarian cancer, and patients without family history. In a postal survey, 354 patients responded. Good acceptance of the MICRA was observed, and previously described good psychometric properties were confirmed. A significant association between MICRA total score and receiving a positive BRCA test result was found. No significant between-group differences were observed with generic distress instruments. Time since cancer diagnosis, test result, and survey showed no significant associations with MICRA scores. Internal consistencies of instruments were adequate. Exploratory and confirmatory factor analyses showed adequate fit indices for a three factor solution of the MICRA, but further refinement of the items should be considered. In conclusion, the specific types of worry and distress most relevant to receiving genetic testing irrespective of family history were not captured by the generic distress instruments. The MICRA was supported as a useful tool for detection of mental distress related to genetic testing and risk evaluation.

Entities:  

Keywords:  Anxiety; BRCA; MICRA; Oncology; Ovarian cancer

Mesh:

Substances:

Year:  2015        PMID: 25980896     DOI: 10.1007/s10689-015-9811-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  20 in total

1.  Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?

Authors:  Chanita Hughes Halbert; Jill E Stopfer; Jasmine McDonald; Benita Weathers; Aliya Collier; Andrea B Troxel; Susan Domchek
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

2.  Psychosocial aspects of hereditary cancer (PAHC) questionnaire: development and testing of a screening questionnaire for use in clinical cancer genetics.

Authors:  W Eijzenga; E M A Bleiker; D E E Hahn; I Kluijt; G N Sidharta; C Gundy; N K Aaronson
Journal:  Psychooncology       Date:  2014-01-20       Impact factor: 3.894

3.  Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results.

Authors:  Suzanne C O'Neill; Tiffani DeMarco; Beth N Peshkin; Sarah Rogers; Jessica Rispoli; Karen Brown; Heiddis Valdimarsdottir; Marc D Schwartz
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-11-15       Impact factor: 3.908

4.  A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire.

Authors:  David Cella; Chanita Hughes; Amy Peterman; Chih-Hung Chang; Beth N Peshkin; Marc D Schwartz; Lari Wenzel; Amy Lemke; Alfred C Marcus; Caryn Lerman
Journal:  Health Psychol       Date:  2002-11       Impact factor: 4.267

5.  Design and psychometric evaluation of the Psychological Adaptation to Genetic Information Scale.

Authors:  Catherine Y Read; Donna J Perry; Mary E Duffy
Journal:  J Nurs Scholarsh       Date:  2005       Impact factor: 3.176

6.  Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes.

Authors:  Suzanne C O'Neill; Christine Rini; Rachel E Goldsmith; Heiddis Valdimarsdottir; Lawrence H Cohen; Marc D Schwartz
Journal:  Psychooncology       Date:  2009-10       Impact factor: 3.894

7.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

8.  The development of a cancer genetic-specific measure of coping: the GRACE.

Authors:  C Phelps; P Bennett; H Jones; K Hood; K Brain; A Murray
Journal:  Psychooncology       Date:  2010-08       Impact factor: 3.894

9.  Impact of Event Scale: a measure of subjective stress.

Authors:  M Horowitz; N Wilner; W Alvarez
Journal:  Psychosom Med       Date:  1979-05       Impact factor: 4.312

10.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

View more
  11 in total

Review 1.  Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature.

Authors:  Lucia Lombardi; Sonia M Bramanti; Alessandra Babore; Liborio Stuppia; Carmen Trumello; Ivana Antonucci; Alessandra Cavallo
Journal:  Support Care Cancer       Date:  2019-06-15       Impact factor: 3.603

2.  Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma.

Authors:  Amelia K Smit; Ainsley J Newson; Megan Best; Caro-Anne Badcock; Phyllis N Butow; Judy Kirk; Kate Dunlop; Georgina Fenton; Anne E Cust
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

3.  Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.

Authors:  Heidi S Lumish; Hallie Steinfeld; Carrie Koval; Donna Russo; Elana Levinson; Julia Wynn; James Duong; Wendy K Chung
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

4.  Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.

Authors:  Rachel A Pozzar; Fangxin Hong; Niya Xiong; Jill E Stopfer; Manan M Nayak; Meghan Underhill-Blazey
Journal:  Fam Cancer       Date:  2021-03-10       Impact factor: 2.375

5.  A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care.

Authors:  Jeanna M McCuaig; Emily Thain; Janet Malcolmson; Sareh Keshavarzi; Susan Randall Armel; Raymond H Kim
Journal:  Curr Oncol       Date:  2021-04-08       Impact factor: 3.677

6.  Patient-Centered Care in Breast Cancer Genetic Clinics.

Authors:  Anne Brédart; Amélie Anota; Julia Dick; Violetta Kuboth; Olivier Lareyre; Antoine De Pauw; Alejandra Cano; Dominique Stoppa-Lyonnet; Rita Schmutzler; Sylvie Dolbeault; Jean-Luc Kop
Journal:  Int J Environ Res Public Health       Date:  2018-02-12       Impact factor: 3.390

7.  Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.

Authors:  Anne Brédart; Jean-Luc Kop; Julia Dick; Alejandra Cano; Antoine De Pauw; Amélie Anota; Joan Brunet; Peter Devilee; Dominique Stoppa-Lyonnet; Rita Schmutzler; Sylvie Dolbeault
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

8.  Novel Interactive Tool for Breast and Ovarian Cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study.

Authors:  Elizabeth A Hibler; Angela J Fought; Kiarri N Kershaw; Rebecca Molsberry; Virginia Nowakowski; Deborah Lindner
Journal:  J Med Internet Res       Date:  2022-02-24       Impact factor: 7.076

9.  Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?

Authors:  Jeanna M McCuaig; Sarah E Ferguson; Danielle Vicus; Karen Ott; Tracy L Stockley; Raymond H Kim; Kelly A Metcalfe
Journal:  Hered Cancer Clin Pract       Date:  2022-04-13       Impact factor: 2.857

10.  Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.

Authors:  Julie O Culver; Charité N Ricker; Joseph Bonner; John Kidd; Duveen Sturgeon; Rachel Hodan; Kerry Kingham; Katrina Lowstuter; Nicolette M Chun; Alexandra P Lebensohn; Courtney Rowe-Teeter; Peter Levonian; Katlyn Partynski; Karlena Lara-Otero; Christine Hong; Jennifer Morales Pichardo; Meredith A Mills; Krystal Brown; Caryn Lerman; Uri Ladabaum; Kevin J McDonnell; James M Ford; Stephen B Gruber; Allison W Kurian; Gregory E Idos
Journal:  Cancer       Date:  2020-12-15       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.